Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:vildagliptin
|
| gptkbp:approvedBy |
gptkb:European_Union
|
| gptkbp:ATCCode |
A10BH02
|
| gptkbp:combinationProduct |
gptkb:Galvus_Met
|
| gptkbp:compatibleWith |
gptkb:United_States
|
| gptkbp:contraindication |
gptkb:diabetic_ketoacidosis
type 1 diabetes |
| gptkbp:drugClass |
DPP-4 inhibitor
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Galvus
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:marketedAs |
2007
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness headache hypoglycemia (when combined with sulfonylureas) |
| gptkbp:usedFor |
gptkb:type_2_diabetes_mellitus
|
| gptkbp:bfsParent |
gptkb:Novartis
|
| gptkbp:bfsLayer |
4
|